Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)

R

Rennes University Hospital

Status

Completed

Conditions

Multiple Sclerosis

Treatments

Other: Biomarkers analysis

Study type

Observational

Funder types

Other

Identifiers

NCT04510350
35RC19_8880_CISCO

Details and patient eligibility

About

The objective of CISCO is therefore to identify prognostic biomarkers of MS activity in early-stage patients.

Enrollment

90 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Patients :

Inclusion Criteria:

  • Patients with clinically isolated syndrome (CIS) participating in the OFSEP cohort (French MS Observatory)
  • At least 18 years of age
  • Diagnosed with MS according to criteria 2017 at the time of their last visit.
  • Non-opposition to participation in the study
  • Having had at least one visit in the year following collection
  • Follow-up for at least 1 year after collection.
  • Having signed the OFSEP consent

Exclusion Criteria:

CIS patients with progressive MS

Healthy volunteers :

Inclusion Criteria:

  • Age 18 years or older
  • Having participated in the ABCD-SEP clinical trial promoted by the Rennes University Hospital (NCT03744351).
  • Matched on age and sex to patients of interest in the OFSEP cohort
  • Not having objected to participation in the study

Exclusion Criteria:

Persons of full age subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty

Trial design

90 participants in 2 patient groups

MS CIS+
Treatment:
Other: Biomarkers analysis
Healthy volunteers
Treatment:
Other: Biomarkers analysis

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems